ArticleBriefings in bioinformatics2025
DS-MVP: identifying disease-specific pathogenicity of missense variants by pre-training representation.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SomaMutDB 2.0: A comprehensive database for exploring somatic mutations and their functional impact in normal human tissues.Nucleic acids research · 2026Article
- Precision in prediction: tailoring machine learning models for breast cancer missense variants pathogenicity prediction.Briefings in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Accurately predicting the pathogenicity of missense variants is crucial for improving disease diagnosis and advancing clinical research. However, existing computational methods primarily focus on general pathogenicity predictions, overlooking assessments of disease-specific conditions. In this study, we propose DS-MVP, a method capable of predicting disease-specific pathogenicity of missense variants in human genomes. DS-MVP first leverages a deep learning model pre-trained on a large general pathogenicity dataset to learn rich representation of missense variants. It then fine-tunes these representations with an XGBoost model on smaller datasets for specific diseases. We evaluated the learned representation by testing it on multiple binary pathogenicity datasets and gene-level statistics, demonstrating that DS-MVP outperforms existing state-of-the-art methods, such as MetaRNN and AlphaMissense. Additionally, DS-MVP excels in multi-label and multi-class classification, effectively classifying disease-specific pathogenic missense variants based on disease conditions. It further enhances predictions by fine-tuning the pre-trained model on disease-specific datasets. Finally, we analyzed the contributions of the pre-trained model and various feature types, with gene description corpus features from large language model and genetic feature fusion contributing the most. These results underscore that DS-MVP represents a broader perspective on pathogenicity prediction and holds potential as an effective tool for disease diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.